Vaccine Peptide Derived from XAGE-1 to Prevent Tumor Growth
Posted Jun 15 2010 5:00pm
Description of Invention: This invention describes a novel peptide derived from the protein XAGE-1 which is expressed specifically in cancer cells of prostate and breast cancer, as well as Ewing's sarcoma. This peptide is able to bind to human HLA-A2 molecules and to induce specific cytotoxic T lymphocyte response in vivo.
This peptide has therapeutic potential as an immunogen, and might induce cancer specific immune responses in cancer patients, which may cause regression of the cancer or prevent cancer metastasis.
Portfolios: Cancer Cancer - Therapeutics In-vitro Data
For Additional Information Please Contact: David Lambertson Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4632 Fax: 301-402-0220